Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study)

Tobias Welte, R. Phillip Dellinger, Henning Ebelt, Miguel Ferrer, Steven M. Opal, Mervyn Singer, Jean-Louis Vincent, Karl Werdan, Ignacio Martin-Loeches, Jordi Almirall, Antonio Artigas, Jose Ignacio Ayestaran, Sebastian Nuding, Ricard Ferrer, Gonzalo Sirgo Rodriguez, Manu Shankar-Hari, Francisco Alvarez-Lerma, Reimer Riessen, Josep-Maria Sirvent, Stefan KlugeKai Zacharowski, Juan Bonastre Mora, Harald Lapp, Gabriele Woebker, Ute Achtzehn, David Brealey, Axel Kempa, Miguel Sanchez Garcia, Joerg Brederlau, Matthias Kochanek, Henrik Peer Reschreiter, Matthew P. Wise, Bernd H. Belohradsky, Iris Bobenhausen, Benjamin Dalken, Patrick Dubovy, Patrick Langohr, Monika Mayer, Joerg Schuettrumpf, Andrea Wartenberg-Demand, Ulrike Wippermann, Daniele Wolf, Antoni Torres

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)438-448
JournalIntensive Care Medicine
Volume44
Issue number4
DOIs
Publication statusPublished - Apr 2018

Keywords / Materials (for Non-textual outputs)

  • Trimodulin
  • Polyclonal antibody
  • Severe community-acquired pneumonia
  • Add-on therapy
  • Immunoglobulin M

Cite this